Whether TNF inhibitors prevent structural damage in ankylosing spondylitis remains a controversial topic, as three prospective trials failed to show any evidence to support this notion. However, data are accumulating from retrospective analyses of well-characterized cohorts of patients that could provide the solution to this controversy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211544 (2017).
van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).
van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063–3070 (2008).
van der Heijde, D. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).
Haroon, N. et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645–2654 (2013).
Maas, F. et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 69, 1011–1019 (2017).
Baraliakos, X. et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann. Rheum. Dis. 73, 710–715 (2014).
Smolen, J. S. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211734 (2017).
van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978–991 (2017).
Braun, J. et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis [abstract]. Ann. Rheum. Dis. 69 (suppl 10), 3L (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.D. declares that he has acted on the advisory board for or received research grants from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB.
Rights and permissions
About this article
Cite this article
Deodhar, A. TNF inhibitors and structural damage in ankylosing spondylitis. Nat Rev Rheumatol 14, 5–6 (2018). https://doi.org/10.1038/nrrheum.2017.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.197